SG176187A1 - A anti-tumor chinese drugs preparation comprising lucidum spores oil and preparation method thereof - Google Patents
A anti-tumor chinese drugs preparation comprising lucidum spores oil and preparation method thereof Download PDFInfo
- Publication number
- SG176187A1 SG176187A1 SG2011085867A SG2011085867A SG176187A1 SG 176187 A1 SG176187 A1 SG 176187A1 SG 2011085867 A SG2011085867 A SG 2011085867A SG 2011085867 A SG2011085867 A SG 2011085867A SG 176187 A1 SG176187 A1 SG 176187A1
- Authority
- SG
- Singapore
- Prior art keywords
- lucidum spores
- atractylodes rhizome
- preparation
- lucidum
- oil mixture
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 55
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 24
- 239000003390 Chinese drug Substances 0.000 title 1
- 241000132012 Atractylodes Species 0.000 claims abstract description 91
- 239000000203 mixture Substances 0.000 claims abstract description 83
- 239000003814 drug Substances 0.000 claims abstract description 47
- 239000003921 oil Substances 0.000 claims description 105
- 238000000605 extraction Methods 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 41
- 239000002245 particle Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000000227 grinding Methods 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 8
- 239000010779 crude oil Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007902 hard capsule Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 201000011510 cancer Diseases 0.000 abstract description 25
- 230000001603 reducing effect Effects 0.000 abstract description 9
- 230000036737 immune function Effects 0.000 abstract description 8
- 230000001105 regulatory effect Effects 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 6
- 208000031971 Yin Deficiency Diseases 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 description 41
- 238000012360 testing method Methods 0.000 description 25
- 238000002512 chemotherapy Methods 0.000 description 22
- 238000001959 radiotherapy Methods 0.000 description 19
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 16
- 238000001356 surgical procedure Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 239000007779 soft material Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000010200 validation analysis Methods 0.000 description 8
- 239000000341 volatile oil Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100278779A CN101596225B (zh) | 2009-05-18 | 2009-05-18 | 一种含灵芝孢子油的抗肿瘤中药制剂及其制备方法 |
PCT/CN2009/000570 WO2010133009A1 (zh) | 2009-05-18 | 2009-05-25 | 一种含灵芝孢子油的抗肿瘤中药制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG176187A1 true SG176187A1 (en) | 2011-12-29 |
Family
ID=41417942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011085867A SG176187A1 (en) | 2009-05-18 | 2009-05-25 | A anti-tumor chinese drugs preparation comprising lucidum spores oil and preparation method thereof |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101596225B (zh) |
SG (1) | SG176187A1 (zh) |
WO (1) | WO2010133009A1 (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094766C (zh) * | 1999-11-19 | 2002-11-27 | 中国科学院南京地理与湖泊研究所科技开发公司 | 一种灵芝孢子的超临界加工方法 |
CN1163252C (zh) * | 2000-05-25 | 2004-08-25 | 黄亚平 | 辅助治疗肿瘤的药物及其制备方法 |
CN100352489C (zh) * | 2004-01-16 | 2007-12-05 | 万忠琦 | 治疗类风湿关节炎犬骨复方药剂 |
CN1557452A (zh) * | 2004-02-10 | 2004-12-29 | 西安绿谷制药有限公司 | 一种抗肿瘤中药及其制备方法 |
CN101129540B (zh) * | 2007-05-29 | 2010-09-08 | 南京中山制药有限公司 | 一种用于健脾胃、消痞满的中药组合物及其制备工艺和应用 |
CN101084934A (zh) * | 2007-06-22 | 2007-12-12 | 广州汉方现代中药研究开发有限公司 | 灵芝孢子油液体胶囊及制备方法 |
CN101450165B (zh) * | 2007-11-29 | 2011-06-29 | 北京九九方元保健品经销有限公司 | 一种抗癌中药复方灵芝制剂及其制备方法 |
-
2009
- 2009-05-18 CN CN2009100278779A patent/CN101596225B/zh active Active
- 2009-05-25 SG SG2011085867A patent/SG176187A1/en unknown
- 2009-05-25 WO PCT/CN2009/000570 patent/WO2010133009A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN101596225B (zh) | 2012-12-26 |
CN101596225A (zh) | 2009-12-09 |
WO2010133009A1 (zh) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101429254B (zh) | 一种白及多糖及其制备方法和新用途 | |
CN104644697B (zh) | 灵芝超微粉的制备方法及其应用 | |
CN105859903A (zh) | 一种北沙参多糖及其制备方法和应用 | |
JP6389958B2 (ja) | 瓦草5環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
CN1745843A (zh) | 一种抗癌中药复方制剂及其制备方法 | |
CN100574768C (zh) | 一种抗癌药物组合物及其制备方法和用途 | |
CN107551001B (zh) | 一种用于防治酒精性肝损伤的中药复合物及其制法 | |
CN103751225B (zh) | 蛹虫草抗肿瘤活性组分的提取方法及其应用 | |
CN107773753B (zh) | 一种含有美洲大蠊和博来霉素的药物及其应用 | |
CN105106816A (zh) | 保护化学性肝损伤的中药保健品制剂及其制备方法 | |
TWI610676B (zh) | 神經細胞死抑制劑、抗阿茲海默症劑、抗腦機能減退劑、具有抗阿茲海默症作用或抗腦機能減退作用的醫藥品及神經細胞死抑制劑的製造方法 | |
CN112057522A (zh) | 一种组合物及其制备方法 | |
KR101893812B1 (ko) | 13가지 글리세리드를 포함한 의이인오일, 제제 및 그 응용 | |
CN103191143B (zh) | 一种强心苷化合物的用途 | |
SG176187A1 (en) | A anti-tumor chinese drugs preparation comprising lucidum spores oil and preparation method thereof | |
CN107854630B (zh) | 米秕糠提取物以及制备方法和应用 | |
CN1686184A (zh) | 以石斛为原料的软胶囊及制备方法 | |
CN113797235A (zh) | 一种具有护肝作用的复方灵芝孢子油的制备方法 | |
CN102727867B (zh) | 一种抗肿瘤用药物组合物及应用、试剂盒及包装件 | |
CN102028698B (zh) | 一种治疗结肠癌的药物及其制备方法 | |
AU2021105119A4 (en) | Drug for treating ovarian cancer, and preparation method and use thereof | |
CN1279934C (zh) | 一种治疗恶性实体瘤的中药药物组合物及其制备方法 | |
CN1817359A (zh) | 治疗妇科疾病的中药制剂及其制备方法 | |
CN117257848A (zh) | 黑芝麻色素在制备用于治疗和/或改善脂肪肝的药物和/或食品中的应用 | |
CN103417670B (zh) | 一种降血脂、抗动脉粥样硬化的药物组合物及其制备方法 |